
IndraLab
Statements
sparser
"SPR experiments from Tran et al. that examined the KRAS-CRAF interaction found that the presence of the CRD increases the binding affinity to KRAS significantly. xref The authors conclude that the CRD is important for differentiating between the RAS GTPase superfamily, even though high sequence homology exists between the switch-I region and the RBDs of RAF. xref Interestingly, our results show that the CRD alone does not affect the affinity of BRAF towards HRAS or KRAS, with binding affinity values within the same nanomolar range for constructs NT2-4."
sparser
"Utilising our first in class cell-penetrating disruptor peptide therapy (DRx-170), we present proof-of-principle data which demonstrates that selective disruption of the pro-oncogenic c-RAF–PDE8A PPI is an encouraging and differentiated approach to inhibiting human KRAS–c-RAF dependent PDAC cell proliferation, adhesion, and migration (Fig. xref )."
reach
"Although the K-Ras/Raf-RBD interaction was readily detectable upon co-expression in a single cell line, or following lysis of co-cultured cell lines separately expressing K-Ras and RBD, bearing in mind the limitations of our assay, we were unable to detect the interaction in the intact, co-cultured cell lines or upon treatment of the Raf-RBD-expressing cells with exosomes containing K-Ras."
sparser
"We next examined the effects of KRB-456 on the levels of KRAS bound to GTP and on the binding of KRAS to RAF1 in intact Panc0203 and Panc1 human pancreatic cancer cells that harbor mt KRAS G12D. To this end, we first treated these cells with various concentrations of KRB-456 and processed the cells for viability assays, immunoprecipitation, GST-RBD pulldown, and western blotting as described in Materials and Methods. xref shows that KRB-456 inhibited the viability of Panc0203 and Panc1 cells in a concentration-dependent manner with IC 50 values of 4.9 ± 0.7 µmol/L and 14.8 ± 2.7 µmol/L, respectively."
sparser
"We next treated Panc0203 and Panc1 cells with KRB-456 for 15 minutes, lysed the cells, and determined the effects of KRB-456 on the levels of GTP-bound KRAS by GST-RBD pulldown assays and the binding of KRAS to RAF1 by co-immunoprecipitation assays as described in the Materials and Methods. xref shows that GST-RBD was able to pull down GTP-bound KRAS in Panc0203 and Panc1 cells treated with vehicle, and that treatment with KRB-456 significantly decreased the GTP-KRAS cellular levels."
sparser
"KRB-456 binds with high affinity to KRAS G12D and KRAS G12V, decreases the cellular levels of GTP-bound KRAS, inhibits the binding of KRAS to RAF1 in pancreatic cancer cells, and inhibits in vivo tumor growth of subcutaneous and orthotopic xenografts from patients with pancreatic cancer."
sparser
"KRB-456 binds KRAS (ITC and protein NMR data), inhibits the binding of KRAS to RAF1 in vitro (alpha screen and GST-RBD pulldown) as well as in intact cancer cells (co-immunoprecipitation with KRAS and blotting with RAF-1 and GST-RBD pulldown) and inhibits the immediate RAS/RAF downstream effector P-MEK clearly demonstrating that KRB-456 engages its target and suppresses KRAS oncogenic signaling in pancreatic cancer."
sparser
"In summary, we report here on the discovery of a novel natural product-inspired small molecule, KRB-456, that binds a dynamic allosteric binding pocket within the switch-I/II region of KRAS G12D, suppresses the levels of KRAS bound to GTP and inhibits the binding of KRAS to RAF1 in human pancreatic cancer cells that harbor KRAS G12D. The fact that KRB-456 thwarted the subcutaneous and orthotopic growth in vivo of PDXs from patients with pancreatic cancer that relapsed after chemotherapy and radiotherapy suggests that it may overcome drug resistance of these tumors."
sparser
"For example, it is likely that other SWI residues are important for mediating mTORC2 activation, such as P35 and I37 which correspond to residues P37 and I39 in Rheb previously shown to promote its binding to mTOR ( xref , xref ), as well as other residues in the allosteric domain such as R149, D153, and Y157 found to be involved in the interaction of human K-Ras with the cysteine-rich domain of Raf1 ( xref )."
reach
"The results also provide direct evidence in individual cells that post-translational modification of K-Ras and its localization at the plasma membrane (PM) were not essential for the interaction of K-Ras and Raf-1, whereas the interaction of Grb2 and K-Ras did depend on the PM localization of K-Ras."
reach
"Using this BEVL-BiFC system, we provided direct evidence in individual cells that post-translational modification of K-Ras and its PM localization were not essential for the interaction between K-Ras and Raf-1, while the interaction of Grb2 and K-Ras depended on PM localization of K-Ras."
sparser
"Co-precipitation of Kras with GST-Raf1-RBD was significantly decreased in cells expressing STAND-Y13-259 when compared to those expressing STAND-A36 or the mock vector control (Fig. xref ), indicating that intracellular STAND-Y13-259 interferes with the interaction of activated Kras and Raf1 by binding to Kras."
sparser
"We have combined several different techniques – phosphoramidite synthesis, one-bead-one-compound library synthesis, fluorescence-activated bead sorting, and tandem mass spectrometry – to create a unique methodology for the selection of novel phosphoestamers that selectively inhibit protein–protein interactions between mutant KRAS G12D and RAF1."
sparser
"We also analyzed the potential impact of ubiquitination at K147 on the interaction of KRAS with C-RAF CRD ( xref and xref , xref ). xref and shows that CRD-interacting residues of KRAS do not make direct contact with ubiquitin, suggesting that they are available for interaction with RAF CRD in mUbKRAS 147 ."
sparser
"While interaction based on Venus signal between K-Ras4B G12D and C-Raf in membrane was observed at 81.60 ± 13.24 of the cells, interaction between K-Ras4B G12D/K101D/R102E and C-Raf was observed at 28.63 ± 8.97 and interaction between K-Ras4B G12D/R41E/K42D and C-Raf was observed at 5.63 ± 1.43 of the transfected cells. ( xref – xref )."
sparser
"In KRAS G12C mutant tumor cells, Aurora-A facilitates the interaction between KRAS and C-RAF and is associated with adaptive reactivation of KRAS after KRAS G12C inhibitor treatment. xref Combination of an Aurora-A inhibitor and a KRAS G12C inhibitor shows synergistic effect in vitro and in vivo."
sparser
"Binding of MRTX 1133 prevented the formation of KRAS G12D /GTP/RAF1 complex, inhibited signaling in cell lines and also showed in vivo tumor regression in 04.03 xenograft model of pancreatic cancer.[ xref ] Investigational New Drug application for MRTX 1133 is planned in the second half of 2022."
reach
"This Switch I conformation in this structure is different from the lower resolution structure (PDB: 6E6F) despite both being in the State 1 conformation (the dynamic Switch I is captured in two different snapshots as observed in two different crystal forms) and is clearly different from the State 2 conformation of KRAS bound to RAF1-RBD (Fig. 4b)."
reach
"We next treated Panc0203 and Panc1 cells with KRB-456 for 15 minutes, lysed the cells, and determined the effects of KRB-456 on the levels of GTP-bound KRAS by GST-RBD pulldown assays and the binding of KRAS to RAF1 by co-immunoprecipitation assays as described in the Materials and Methods."
reach
"KRB-456 binds with high affinity to KRAS G12D and KRAS G12V, decreases the cellular levels of GTP-bound KRAS, inhibits the binding of KRAS to RAF1 in pancreatic cancer cells, and inhibits in vivo tumor growth of subcutaneous and orthotopic xenografts from patients with pancreatic cancer."
sparser
"To this end, we treated MiaPaCa2 cells with FGTI-2734 as described above, and processed the cells for RAF-1 immunoprecipitation, followed by immunoblotting of KRAS and KSR, a scaffolding protein that binds RAF-1 and mediates RAS activation of RAF-1. xref shows that in the absence or presence of FGTI-2734, RAF-1 was able to bind KRAS, suggesting that both membrane and cytosolic KRAS are able to bind RAF-1."
sparser
"Our pharmacological and genetic approaches show that cytosolic KRAS is still able to bind one of its major effectors RAF-1 but is not able to activate it, possibly due to inhibition of binding to the scaffolding protein KSR (see xref ) which plays a major role in RAS activation of Raf ( xref )."
reach
"In contrast, an apparent cytosolic distribution pattern was observed in cells co-transfected with mcerulean-Raf1 and EGFP-K-RasC185S, suggesting that the membrane localization of K-Ras and Raf1 complexes is not entirely dependent on K-Ras, and that other factors, such as the irreversible conformation formed between K-Ras and Raf1 may play a role."
reach
"However, there are still some unresolved issues regarding their interactions such as where and how the activation of Raf1 and K-Ras occurs in cells, whether K-Ras and Raf1 simply traffic together or are part of a larger multicomponent signaling complexes, as well as whether the ultimate cellular localization of the K-Ras and Raf1 complexes is independent of the original Raf1 and K-Ras locations."
reach
"Results above show that the BiFC system composed of Raf1 and K-Ras is sensitive for EGF stimulation, and the trend of BiFC fluorescence change is consistent with previous report on the K-Ras response to EGF stimulation [XREF_BIBR], indicating that the activation of K-Ras can promote its complex formation with Raf1, and the Raf1 and K-Ras interaction in BiFC system has not been interfered by the fluorescent protein fragments they connected, and this system is suitable for further studies of Raf1 and K-Ras interaction."
reach
"As shown in XREF_FIG, sub-cellular localization of the K-Ras and Raf1 complexes which was mainly distributed in the cell membrane (XREF_FIG) varied from the K-Ras-C185S and Raf1, which was mainly localized in the cytoplasm (XREF_FIG), and these distinct subcellular localizations were further confirmed in different imaging depth (XREF_FIG), indicating that the C-terminal CAAX site is the determinant for sub-cellular localization of K-Ras and Raf1 complexes, which is consistent with previous reports [XREF_BIBR]."
reach
"Moreover, significant co-localized signal between K-Ras and Raf1 was found in the cell membrane (XREF_FIG), suggesting that K-Ras affects the cellular localization of Raf1, and the cellular interaction between K-Ras and Raf1 is likely to facilitate the membrane binding ability of Raf1."
sparser
"Mutational scanning of KRAS-RAF1 complexes identified key binding affinity hotspots, including Y40, E37, D38, and D33, and together with the MM-GBSA analysis revealed the hotspots leverage synergistic electrostatic and hydrophobic binding interactions in stabilizing the KRAS-RAF1 complexes."
reach
"These 3D coculture results, coupled with the in vivo PDX results showing that KRB-456 is effective against tumors derived from relapsed patients (two of the biopsies were resected from patients who relapsed after treatment with 5-FU, gemcitabine, capecitabine, and/or radiation), suggest that KRB-456 can overcome resistance to chemotherapy and radiotherapy.KRB-456 binds KRAS (ITC and protein NMR data), inhibits the binding of KRAS to RAF1 in vitro (alpha screen and GST-RBD pulldown) as well as in intact cancer cells (co-immunoprecipitation with KRAS and blotting with RAF-1 and GST-RBD pulldown) and inhibits the immediate RAS/RAF downstream effector P-MEK clearly demonstrating that KRB-456 engages its target and suppresses KRAS oncogenic signaling in pancreatic cancer."
reach
"Therefore, at least in the case of pancreatic cancer where the tumors appear to be highly dependent on energy from autophagy especially when KRAS or its downstream effectors are inhibited, combination of KRB-456 with autophagy inhibitors may also prove to be efficacious.In summary, we report here on the discovery of a novel natural product-inspired small molecule, KRB-456, that binds a dynamic allosteric binding pocket within the switch-I/II region of KRAS G12D, suppresses the levels of KRAS bound to GTP and inhibits the binding of KRAS to RAF1 in human pancreatic cancer cells that harbor KRAS G12D."
sparser
"Zhang and others described that K-RAS4A interacts with Raf-1 with higher affinity than K-RAS4B, leading to increased RAF1-1MEK-ERK signalling cascade, and that K-RAS4A showed increased anchorage-independent growth in assays that compared K-RAS4A- and K-RAS4B-transformed NIH 3T3 cells ( xref )."
sparser
"The results also provide direct evidence in individual cells that post-translational modification of K-Ras and its localization at the plasma membrane (PM) were not essential for the interaction of K-Ras and Raf-1, whereas the interaction of Grb2 and K-Ras did depend on the PM localization of K-Ras."
sparser
"Moreover, significant co-localized signal between K-Ras and Raf1 was found in the cell membrane ( xref ), suggesting that K-Ras affects the cellular localization of Raf1, and the cellular interaction between K-Ras and Raf1 is likely to facilitate the membrane-binding ability of Raf1."
sparser
"The role of D154 and α4-α5 helices in RAS dimerization also becomes problematic when one takes into account the modeling of the KRAS-CRAF (RBD-CRD) complex on the membrane using previously identified CRD membrane-interacting residues into the lipid bilayer which places KRAS helices α4 and α5 in membrane contact xref , consistent with an earlier study using FRET vectors xref ."
sparser
"Using this BEVL-BiFC system, we provided direct evidence in individual cells that post-translational modification of K-Ras and its PM localization were not essential for the interaction between K-Ras and Raf-1, while the interaction of Grb2 and K-Ras depended on PM localization of K-Ras."